hygiea.tech
B2B healthcare hygiene, compliance, and safety-ops SaaS
Latest from the blog
- Healthcare Communication Standards: HL7 FHIR vs Legacy Systems — Build or Buy Decision Guide 2026
- Waived-test competency records: verify CLIA checklist and compare like-for-like
- Lab Safety Operations Guide: CLIA-101 Protocol vs 2% QC Failure Trigger
- Early Breast Cancer Spread Risk: 70-Gene MammaPrint to Skip Chemo in 46%
- CLIA PT Corrective Action Deferral: Verify Delay Risks Before You Commit
- CLIA waived testing errors: 30-day fix window vs 2% QC trigger in family medicine
- Lab turnaround goals: 2026 HL7 FHIR (Fast Healthcare Interoperability Resources) vs 25% error cap — Build or Buy
- Canada health reform: how to verify 2026 deadlines before committing
Knowledge Base
- What are Avantor's risk channels and how does responsive allocation impact operations?
- How does Danaher's Microsoft AI partnership impact its valuation and safety operations?
- Why is albemarle stock underperforming compared to competitors on friday?
- What is the current Omnicell stock price and historical performance?
- How does Danaher's Q3 investment activity impact B2B healthcare hygiene compliance?
- What did Danaher Corporation present at the Jefferies Global Healthcare Conference 2026?
- How does Omnicell use its net cash to challenge Pyxis?
- What does David Greenberg's $155,513 ICUM stock sale mean for investors?